Interview prep for Site Reliability Engineer roles
SRE interviews focus heavily on systems thinking, operational excellence, and incident response scenarios.. Explore key insights and preparation tips to help you excel in your interview process.
CODING PREP
Medium-level coding with infrastructure focus
SRE coding questions emphasize automation, monitoring, and distributed systems problems rather than pure algorithms.
DifficultyMedium
Focus on scripting, data structures for metrics, and system automation
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Exceptional Value Proposition
Baltimore offers approximately 40% lower housing costs compared to San Francisco, with median home prices around $200K versus $1.3M+ in the Bay Area. This dramatic cost difference allows Site Reliability Engineers to maximize their earning potential while enjoying a high quality of life in a historic East Coast city with excellent proximity to DC and NYC tech corridors.
San Francisco baseline100
Baltimore (28% lower)72
Favorable Talent Market
Baltimore's emerging tech ecosystem creates excellent opportunities for SREs with significantly less competition than saturated markets. Growing demand from local startups and established companies relocating operations.
Baltimore
San Francisco
Austin
Frequently Asked Questions
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
Pearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.